Welcome to our dedicated page for AEQUUS PHARMACEUTICAL news (Ticker: AQSZF), a resource for investors and traders seeking the latest updates and insights on AEQUUS PHARMACEUTICAL stock.
Aequus Pharmaceuticals Inc. (AQSZF) is a specialty pharmaceutical company focused on developing and commercializing high-quality products. Founded in 2015, the company has grown multiple products in therapeutic areas like Ophthalmology, Optometry, Transplant, and Rare Disease. Aequus plans to expand its Canadian commercial platform through sales, marketing, and strategic partnerships.
The company's Evolve® range of products is currently on hold in Canada due to a switch in MDSAP provider by Medicom Healthcare (UK). Once the certification process is complete, sales will resume, reaffirming Aequus' commitment to delivering innovative solutions.
With a dedication to patient well-being and a focus on enhancing the Canadian marketplace, Aequus Pharmaceuticals is poised for continued growth and success.
Aequus Pharmaceuticals Inc. (OTCQB: AQSZF) has announced the granting of incentive stock options to directors, officers, employees, and consultants, totaling 2,775,000 common shares. These options will be exercisable at a price of $0.03 per share over a term of eight years and will vest over three years. This move aligns with the Company's stock option plan and the TSX Venture Exchange policies. Aequus is focused on developing and commercializing specialized pharmaceutical products, particularly in ophthalmology and seeks to expand its Canadian platform through internal development or acquisitions.
Aequus Pharmaceuticals (TSX-V: AQS, OTCQB: AQSZF) has secured a $500,000 loan from CEO Doug Janzen to support the launch of Zimed® PF, a new preservative-free treatment for elevated intraocular pressure in glaucoma patients. The loan carries a 2.5% interest rate and is repayable on demand. Zimed® PF received Health Canada approval last December and is the only multi-dose preservative-free prostaglandin analog available, aimed at reducing side effects linked to preservatives. Aequus plans to use the funds for sales efforts, digital resources, and general working capital as it prepares for a critical product launch.
Aequus Pharmaceuticals Inc. (AQSZF) has received approval from Health Canada for Zimed® PF (Bimatoprost 0.03%), a preservative-free treatment for elevated intraocular pressure in patients with open-angled glaucoma and ocular hypertension. This innovative product, which utilizes a unique multi-dose bottle design, aims to improve patient adherence and reduce the risk of ocular surface disease typically associated with preservatives. The launch is set for 2023, with expectations for strong market uptake in Canada.
FAQ
What is the market cap of AEQUUS PHARMACEUTICAL (AQSZF)?
What is Aequus Pharmaceuticals Inc. focused on?
When will sales of Evolve® products resume in Canada?
What is Aequus' commitment to patients in Canada?
When was Aequus Pharmaceuticals founded?
In which therapeutic areas has Aequus grown products?
How does Aequus plan to expand its Canadian platform?
Why are Evolve® products currently on hold in Canada?
What sets Aequus Pharmaceuticals apart in the market?
Where can I find more information about Aequus Pharmaceuticals?
What is Aequus Pharmaceuticals' stock symbol?
